Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Mar 10, 2026

‘First published on BW Legal World’ By: Safir Anand, Mudit Kaushik and Sehr Anand India has strong design talent, ranging from local craftspeople to

Not Just Made in India – Designed in India The Budget’s Most Strategic Move
News & Updates, Thought Leadership
Mar 10, 2026

‘First published on BW Legal World’ By: Pravin Anand and Dr. Ajai Garg The Summit underscored a broader reality: artificial intelligence is no longer

India AI Impact Summit 2026: Law, Leadership, and India’s AI Moment
Thought Leadership
Feb 13, 2026

‘First published on Enterprise IT World’ By: Subroto Kumar Panda How the 2026 IT Rule Amendments Protect You in the Age of AI In an era where seeing

The Digital Armor – 2026
Thought Leadership
Feb 11, 2026

Authors: Safir Anand, Mudit Kaushik and Sehr Anand The establishment of a new National Institute of Design (NID-East) in India’s eastern region,

Can New NID-East Ignite India’s Design Revolution?